This is a port of Arduino to the RP2040 (Raspberry Pi Pico processor) and RP2350 (Raspberry Pi Pico 2 processor). It uses the bare Raspberry Pi Pico SDK and a custom GCC 14.2/Newlib 4.3 toolchain and ...

A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 versus Q4 2023. Approval in CSCC means that this growth catalyst is ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

Pi, a mathematical constant denoted by the Greek letter π, is the ratio of a circle's circumference C to its diameter d: π = C/d. The circumference of a circle is, in turn, equal to 2πr, where ...

Cancer treatment decisions are complex, requiring consideration of both medical advancements and individual patient needs, including emotional and physical conditions. There is often a gap between the ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT (amivantamab) for the first-line treatment of adult patients with advanced ...

The Pi Network price continued its downtrend this week, reaching a low of $38, its lowest swing in almost three months. It has dived by more than 56% from its all-time high as investors wait for ...

The UK experienced a notable increase in advanced therapy clinical trials in 2024, reaching 187 ongoing trials. This marks a 7% rise from the previous year. Particularly, phase I trials saw an ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...